Amivantamab binds MET on target cells and its Fc region engages immune effector cells (e.g., NK cells, macrophages) via Fcγ receptors, inducing ADCC and ADCP to kill MET-expressing cells; it also promotes receptor internalization/degradation and signaling blockade (antiproliferative).